Bristol-Myers Squibb’s growth portfolio is validating an undervalued patent-cliff recovery, but milvexian and debt determine whether upside extends beyond income.
Overview
Bristol-Myers Squibb is a global, single-segment biopharmaceutical company whose revenues come from product sales, alliances, and licensing royalties. Its portfolio is divided between legacy blockbusters facing generic erosion and newer specialty medicines with longer patent runways. The US contributes approximately 70% of revenue, while more than 70% of channel shipments pass through McKesson, Cardinal Health, and Cencora. **The key investment question is whether Growth Portfolio expansion can replace declining Eliquis, Revlimid, Pomalyst, and Opdivo economics.** Q2 2026 provided strong evidence of execution: revenue was $12.973 billion, up 6% year over year, non-GAAP EPS rose 40% to $2.04, and non-GAAP operating margin expanded 3.4 percentage points to 31.5%. Growth Portfolio revenue increased 15% and represented 59.2% of sales. Management raised FY2026 revenue guidance to $49.0–$50.0 billion and non-GAAP EPS guidance to $6.75–$7.00. Valuation remains discounted at approximately 9.95x forward P/E, about 2.7x EV/Sales, and roughly 9% free-cash-flow yield. Near-term catalysts include Cobenfy Alzheimer’s readouts in late 2026 and pivotal milvexian atrial-fibrillation data in Q1 2027, although debt, IRA pricing pressure, and clinical execution remain material constraints.